[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

US20080319221A1 - Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids - Google Patents

Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids Download PDF

Info

Publication number
US20080319221A1
US20080319221A1 US11/767,298 US76729807A US2008319221A1 US 20080319221 A1 US20080319221 A1 US 20080319221A1 US 76729807 A US76729807 A US 76729807A US 2008319221 A1 US2008319221 A1 US 2008319221A1
Authority
US
United States
Prior art keywords
formula
compound
exemplary embodiments
chosen
reacting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/767,298
Inventor
Bernd Junker
Javier Manero
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Priority to US11/767,298 priority Critical patent/US20080319221A1/en
Assigned to SANOFI-AVENTIS DEUTSCHLAND GMBH reassignment SANOFI-AVENTIS DEUTSCHLAND GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: JUNKER, BERND, MANERO, JAVIER
Priority to PCT/EP2008/004552 priority patent/WO2009000397A1/en
Priority to AU2008267515A priority patent/AU2008267515A1/en
Priority to KR1020097026689A priority patent/KR20100023886A/en
Priority to MX2009012727A priority patent/MX2009012727A/en
Priority to CN200880021496A priority patent/CN101687769A/en
Priority to CA2691065A priority patent/CA2691065A1/en
Priority to BRPI0813120A priority patent/BRPI0813120A2/en
Priority to TW097122784A priority patent/TW200914406A/en
Priority to ARP080102606A priority patent/AR068977A1/en
Priority to UY31165A priority patent/UY31165A1/en
Priority to CL200801857A priority patent/CL2008001857A1/en
Priority to US12/271,236 priority patent/US7678935B2/en
Publication of US20080319221A1 publication Critical patent/US20080319221A1/en
Priority to IL202824A priority patent/IL202824A0/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Definitions

  • Benzyl pentahydroxyhexylcarbamoylundecanoate has the formula I
  • Hal is chosen from Br, Cl, and l, and
  • R1 is an alkyl radical which has from 1 to 18 carbon atoms and in which
  • Hal is chosen from Br, Cl, and l, and
  • R1 is an alkyl radical which has from 1 to 18 carbon atoms and in which
  • Hal is chosen from Br, Cl, and l
  • Hal is chosen from Br, Cl, and l to form a compound of formula Va.
  • Hal is chosen from Br, Cl, and l, to form a compound of formula Va
  • n is an integer from 6 to 17.
  • an alkyl radical is a straight-chain or branched hydrocarbon chain having from one to eighteen carbon atoms, e.g. methyl, ethyl, isopropyl, n-butyl, isobutyl, tert-butyl, hexyl, heptyl, octyl.
  • an aryl radical is a phenyl, naphthyl, or biphenyl radical in which at least one CH group is optionally replaced by O, N, or S.
  • the aryl radicals are optionally substituted by at least one suitable group, e.g.: F, Cl, Br, l, CF 3 , NO 2 , CN, COO(C 1 -C 6 )alkyl, CON[(C 1 -C 6 )alkyl] 2 , cycloalkyl, (C 1 -C 10 )-alkyl, (C 2 -C 6 )-alkenyl, (C 2 -C 6 )-alkynyl, O—(C 1 -C 6 )-alkyl, O—(C 2 -C 6 )-alkenyl, O—(C 2 -C 6 )-alkynyl, O—CO—(C 1 -C 6 )-alkyl, O—CO—(C 1 -
  • glucamine refers to a compound according to the formula:
  • a specific glucamine is D-glucamine represented by the formula:
  • reacting is intended to represent bringing the chemical reactants together under conditions such as to cause the chemical reaction indicated to take place.
  • converting is intended to represent changing one compound into another, for example converting a compound of formula I into a compound of formula II.
  • the compounds described herein may be present in crystalline or amorphous solid forms. Those crystalline forms may include polymorphs and solvates, such as hydrates.
  • Hal is chosen from Br, Cl, and l, and
  • R1 is an alkyl radical which has from 1 to 18 carbon atoms and in which
  • the compound of formula VI is chosen from alkylcarboxylic halides and alkyl haloformates. In some exemplary embodiments, the compound of formula VI is isobutyl chloroformate.
  • Hal is Cl
  • R1 is chosen from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, methyloxy, ethyloxy, propyloxy, isopropyloxy, butyloxy, isobutyloxy, tert-butyloxy, and benzyloxy. In some exemplary embodiments, R1 is isobutyloxy.
  • step a) the compound of formula IV is dissolved in a suitable solvent or solvent mixture in the presence of a suitable base at from ⁇ 30° C. to 70° C., such as from ⁇ 10° C. to 40° C., further such as from ⁇ 5° C. to 0° C.
  • a compound of formula IV may be added over a period of 30-150 minutes, such as 60-120 minutes, to a solution of a compound of formula VI.
  • the solution of a compound of formula VI may be cooled to from ⁇ 10° C. to 30° C., such as from ⁇ 10 to 0° C.
  • step a) a solution of a compound of formula VI in a suitable solvent or solvent mixture which is cooled to from ⁇ 10° C. to 30° C., such as from ⁇ 10° C. to 0° C., is added to a compound of formula IV and a suitable base in a suitable solvent or solvent mixture at from ⁇ 30° C. to 70° C., such as from ⁇ 10° C. to 40° C., further such as from ⁇ 5° C. to 0° C., over a period of 30-150 minutes, such as 60-120 minutes.
  • the reaction mixture in step a), is stirred at from ⁇ 10° C. to 40° C., such as from ⁇ 10° C. to 0° C., for from 15-150 minutes, such as 30-120 minutes.
  • the reaction mixture may then either be used directly in the subsequent reaction or the product formed is isolated.
  • the reaction mixture is used directly.
  • the compound of formula V is isolated by evaporation of the solvent(s) under reduced pressure.
  • the reaction mixture is washed with water before the evaporation.
  • the suitable base used in step a) is chosen from tertiary amines such as triethylamine, ethyldimethylamine, ethyldiisopropylamine, tributylamine, N-ethylmorpholine, tetramethylethylenediamine, guanidine, and alkyl guanidines.
  • the suitable base is chosen from triethylamine and ethyldiisopropylamine.
  • the suitable solvent used in step a) is chosen from aprotic organic solvents such as toluene, chlorobenzene, dichloromethane, ethyl acetate, butyl acetate, diisobutyl ether, diisopropyl ether, tetrahydrofuran, 2-methyltetrahydrofuran, dimethylformamide, N-methylpyrrolidone, and methyl ethyl ketone.
  • the suitable solvent is chosen from ethyl acetate and butyl acetate.
  • a mixture of solvents is used.
  • step b) D-glucamine is added a little at a time over a period of from 5-60 minutes, such as 15-30 minutes, to a solution of a compound of formula V and a suitable base in a suitable solvent or solvent mixture at from ⁇ 10° C. to 40° C., such as from ⁇ 5° C. to 0° C.
  • the suitable base used in step b) is chosen from tertiary amines such as triethylamine, ethyldimethylamine, ethyldiisopropylamine, tributylamine, N-ethylmorpholine, tetramethylethylenediamine, guanidine, and alkyl guanidines.
  • the suitable base is chosen from triethylamine and ethyidiisopropylamine.
  • the suitable solvent used in step b) is chosen from aprotic organic solvents such as toluene, chlorobenzene, dichloromethane, ethyl acetate, butyl acetate, diisobutyl ether, diisopropyl ether, tetrahydrofuran, 2-methyltetrahydrofuran, dimethylformamide, N-methylpyrrolidone, and methyl ethyl ketone.
  • the suitable solvent is chosen from ethyl acetate and butyl acetate.
  • a mixture of solvents is used.
  • the reaction mixture of step b) is stirred for a further period of from 5-120 minutes, such as 30-60 minutes, at from ⁇ 10° C. to 40° C., such as from ⁇ 5° C. to 0° C., subsequently for a further 5-20 hours, such as 12 hours, at from 0 to 30° C., such as from 15° C. to 20° C., and subsequently washed with water at 10° C. to 80° C., such as 50° C. to 70° C., and further such as 60° C.
  • the mixture is subsequently cooled to a temperature sufficient to induce crystallization of the compound of formula I, such as 20° C.
  • the compound of formula I is purified by recrystallization.
  • Hal is chosen from Br, Cl, and l
  • R1 is an alkyl radical which has from 1 to 18 carbon atoms and in which
  • the compound of formula VI is chosen from alkylcarboxylic halides and alkyl haloformates. In some exemplary embodiments, the compound of formula VI is isobutyl chloroformate.
  • Hal is Cl
  • R1 is chosen from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, methyloxy, ethyloxy, propyloxy, isopropyloxy, butyloxy, isobutyloxy, tert-butyloxy, and benzyloxy. In some exemplary embodiments, R1 is isobutyloxy.
  • step a) the compound of formula IV is dissolved in a suitable solvent or solvent mixture in the presence of at least one base at from ⁇ 30° C. to 70° C., such as from ⁇ 10° C. to 40° C., further such as from ⁇ 5° C. to 0° C., and added over a period of 30-150 minutes, such as 60-120 minutes, to a solution of compound of formula VI which is cooled to from ⁇ 10° C. to 30° C., such as from ⁇ 10 to 0° C.
  • a solution of a compound of formula VI in a suitable solvent or solvent mixture is cooled to from ⁇ 10° C. to 30° C., such as from ⁇ 10° C. to 0° C., in a reaction vessel and then is added to a compound of formula IV and a suitable base in a suitable solvent or solvent mixture at from ⁇ 30° C. to 70° C., such as from ⁇ 10° C. to 40° C., further such as from ⁇ 5° C. to 0° C., over a period of 30-150 minutes, such as 60-120 minutes.
  • the reaction mixture in step a) is stirred at from ⁇ 10° C. to 40° C., such as from ⁇ 10° C. to 0° C., for from 15-150 minutes, such as 30-120 minutes.
  • the reaction mixture can then either be used directly in the subsequent reaction or the product formed is isolated.
  • the reaction mixture is used directly.
  • the compound of formula V is isolated by evaporation under reduced pressure.
  • the reaction mixture is washed with water before the evaporation.
  • the suitable base used in step a) is chosen from tertiary amines such as triethylamine, ethyldimethylamine, ethyldiisopropylamine, tributylamine, N-ethylmorpholine, tetramethylethylenediamine, guanidine, and alkyl guanidines.
  • the suitable base is chosen from triethylamine and ethyidiisopropylamine.
  • the suitable solvent used in step a) is chosen from customary organic solvents such as toluene, chlorobenzene, dichloromethane, ethyl acetate, butyl acetate, diisobutyl ether, diisopropyl ether, tetrahydrofuran, 2-methyltetrahydrofuran, dimethylformamide, N-methylpyrrolidone, or methyl ethyl ketone.
  • the suitable solvent is ethyl acetate or butyl acetate.
  • a mixture of solvents is used.
  • step b) the compound of formula IV is added a little at a time to a solution of product V and optionally a suitable base in a suitable solvent or solvent mixture at from ⁇ 10° C. to 40° C., such as from 0° C. to 25° C., over a period of 5-60 minutes, such as 15-30 minutes.
  • the suitable base used in step b) is chosen from tertiary amines such as triethylamine, ethyldimethylamine, ethyldiisopropylamine, tributylamine, N-ethylmorpholine, tetramethylethylenediamine, guanidine, and alkyl guanidines.
  • the suitable base is chosen from triethylamine and ethyidiisopropylamine.
  • the suitable solvent used in step b) is chosen from aprotic organic solvents such as toluene, chlorobenzene, dichloromethane, ethyl acetate, butyl acetate, diisobutyl ether, diisopropyl ether, tetrahydrofuran, 2-methyltetrahydrofuran, dimethylformamide, N-methylpyrrolidone, and methyl ethyl ketone.
  • the suitable solvent is chosen from ethyl acetate and butyl acetate.
  • a mixture of solvents is used.
  • the reaction mixture of step b) is stirred at from ⁇ 10° C. to 40° C., such as from 0° C. to 25° C., for another 5-240 minutes, such as 60-150 minutes.
  • the precipitate formed is filtered and dried, giving a compound of formula VIII.
  • step c) D-glucamine is added a little at a time to a solution of product VIII and optionally a suitable base in a suitable solvent or solvent mixture at from ⁇ 10° C. to 40° C., such as from ⁇ 5° C. to 5° C., over a period of from 5-60 minutes, such as 15-30 minutes.
  • the suitable base used in step c) is chosen from tertiary amines such as triethylamine, ethyldimethylamine, ethyldiisopropylamine, tributylamine, N-ethylmorpholine, tetramethylethylenediamine, guanidine, and alkyl guanidines.
  • the suitable base is chosen from triethylamine and ethyidiisopropylamine.
  • the suitable solvent used in step c) is chosen from aprotic organic solvents such as toluene, chlorobenzene, dichloromethane, ethyl acetate, butyl acetate, diisobutyl ether, diisopropyl ether, tetrahydrofuran, 2-methyltetrahydrofuran, dimethylformamide, N-methylpyrrolidone, and methyl ethyl ketone.
  • the suitable solvent is chosen from ethyl acetate and butyl acetate.
  • a mixture of solvents is used.
  • the reaction mixture in step c) is stirred at from ⁇ 10° C. to 40° C., such as from 10° C. to 25° C., for another 1-20 hours, such as 10-18 hours, and subsequently washed with water at 10° C. to 80° C., such as 50° C. to 70° C.
  • the mixture is subsequently cooled to a temperature sufficient to induce crystallization of the compound of formula I, such as 20° C.
  • the compound of formula I is purified by recrystallization.
  • the compound of formula I which may be obtained as described herein, is converted into a compound of formula II
  • converting the compound of formula I into a compound of formula II comprises reacting the compound of formula I under alkaline conditions, using, for example, aqueous sodium hydroxide or aqueous potassium hydroxide.
  • converting the compound of formula I into a compound of formula II comprises reacting the compound of formula I under enzymatic conditions to form formula II.
  • suitable enzymes include lipases, for example Candida.
  • converting the compound of formula I into a compound of formula II comprises hydrogenating the compound of formula I under suitable conditions.
  • hydrogenating the compound of formula I comprises reacting the compound of formula I with a hydrogen source in the presence of a hydrogenation catalyst.
  • a hydrogenation catalyst such as palladium on carbon (Pd/C), Raney-Nickel, platinum, platinum oxide, or zinc oxide is used.
  • the hydrogen source is chosen from hydrogen gas and ammonium formate.
  • Hal is chosen from Br, Cl, and l
  • R1 is an alkyl radical which has from 1 to 18 carbon atoms and in which
  • reaction conditions for the preparation of a compound of formula V, a compound of formula I, and a compound of formula II are as described herein.
  • reacting the compound of formula II with a compound of formula VII comprises reacting the compound of formula II with suitable peptide coupling reagents in a suitable solvent or solvent mixture, and then further reacting with a compound of formula VII.
  • suitable peptide coupling reagents and solvents or solvent mixtures are described, inter alia, in, for example, A. Speicher et al. In Journal für Praktician Chemie/Chemiker-Zeitung (1998), 340, 581-583; Y. S. Klausner and M. Bodansky, Synthesis, (1972), 453 et seq.; K. Ishihara et al., J. Org. Chem., 61, 4196 (1996); M. Kunishima et al., Tetrahedron 55,13159-13170 (1999), or R. C. Larock: Comprehensive Organic Transformations; VCH, New York, 1989, page 981 et. seq.
  • Hal is chosen from Br, Cl, and l
  • R1 is an alkyl radical which has from 1 to 18 carbon atoms and in which
  • reaction conditions for the preparation of a compound of formula V, a compound of formula VIII, a compound of formula I, a compound of formula II, and a compound of formula III are as described herein.
  • reaction conditions for the preparation of a compound of formula I from a compound of formula V are as described herein.
  • reaction conditions for the preparation of a compound of formula I from a compound of formula Va are as described herein.
  • Hal is chosen from Br, Cl, and l to form a compound of formula Va.
  • the processes for the preparation of a compound of formula Va from a compound of formula IV are as described herein.
  • reaction conditions for the preparation of a compound of formula I from a compound of formula Va are as described herein.
  • Hal is chosen from Br, Cl, and l, to form a compound of formula Va
  • reaction conditions for the preparation of a compound of formula Va from a compound of formula IV and for the preparation of a compound of formula VIII from a compound of formula Va are as described herein.
  • reaction conditions for the preparation of a compound of formula I from a compound of formula VIII are as described herein.
  • Benzyl 12-isobutoxycarbonyloxy-12-oxododecanoate is dissolved in 15 ml of ethyl acetate and admixed at 0° C. with 0.9 g (5.2 mmol) of 2R,3R,4R,5S-6-aminohexane-1,2,3,4,5-pentanol (D-glucamine).
  • the mixture is stirred at 0° C. for one hour, warmed to 20° C. and allowed to stand overnight.
  • the white suspension formed is shaken three times at 65° C. with 20 ml of water at the same temperature.
  • the organic phase is subsequently evaporated to dryness to obtain benzyl 11-(2S,3R,4R,5R-2,3,4,5,6-pentahydroxyhexylcarbamoyl)undecanoate (I).
  • Benzyl 12-isobutoxycarbonyloxy-12-oxododecanoate is admixed with 20 ml of ethyl acetate and admixed at 20° C. with 1.9 g (4.2 mmol) of the monobenzyl ester of dodecanedioic acid. The mixture is stirred for 2.5 hours, and the precipitate formed is filtered off and dried to obtain anhydride of dodecanedicarboxylic monobenzyl ester (VIII).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided are compounds of formula A and formula I: A compound of formula A:
Figure US20080319221A1-20081225-C00001
wherein n is an integer from 6 to 17 and a compound of formula I:
Figure US20080319221A1-20081225-C00002

Description

  • Provided are certain compounds set forth below, certain processes for the preparation of esters of pentahydroxyhexylcarbamoyl alkanoic acids, and certain uses therefore.
  • Benzyl pentahydroxyhexylcarbamoylundecanoate has the formula I
  • Figure US20080319221A1-20081225-C00003
  • and is an intermediate in the preparation of the compound of formula II
  • Figure US20080319221A1-20081225-C00004
  • which in turn is an intermediate in the synthesis of the compound of formula III
  • Figure US20080319221A1-20081225-C00005
  • which is described in U.S. Pat. No. 7,205,290 as having, for example, cholesterol-lowering properties.
  • Provided generally is a process for preparing a compound of formula A
  • Figure US20080319221A1-20081225-C00006
  • wherein n is an integer from 6 to 17 comprising
  • a) reacting a compound of formula B
  • Figure US20080319221A1-20081225-C00007
  • with a compound of VI
  • Figure US20080319221A1-20081225-C00008
  • wherein
  • Hal is chosen from Br, Cl, and l, and
  • R1 is an alkyl radical which has from 1 to 18 carbon atoms and in which
      • at least one —CH2— group of the alkyl radical is optionally replaced by at least one group chosen from —O—, —CO—, —CH═CH—, —C≡C—, and aryl groups, and
      • the alkyl radical is optionally substituted by at least one halogen chosen from F, Cl, Br, and l,
  • to form a compound of formula C
  • Figure US20080319221A1-20081225-C00009
  • and
  • b) reacting the compound of formula C with glucamine to form the compound of formula A.
  • In an exemplary embodiment is provided a process for preparing a compound of formula I
  • Figure US20080319221A1-20081225-C00010
  • comprising
  • a) reacting a compound of formula IV
  • Figure US20080319221A1-20081225-C00011
  • with a compound of formula VI
  • Figure US20080319221A1-20081225-C00012
  • wherein
  • Hal is chosen from Br, Cl, and l, and
  • R1 is an alkyl radical which has from 1 to 18 carbon atoms and in which
      • at least one —CH2— group of the alkyl radical is optionally replaced by at least one group chosen from —O—, —CO—, —CH═CH—, —C≡C—, and aryl groups, and
      • the alkyl radical is optionally substituted by at least one halogen chosen from F, Cl, Br, and l,
  • to form a compound of formula V
  • Figure US20080319221A1-20081225-C00013
  • and
  • b) reacting the compound of formula V with D-glucamine to form the compound of formula I.
  • Also provided is a process for preparing a compound of formula I
  • Figure US20080319221A1-20081225-C00014
  • comprising
  • a) reacting a compound of formula IV
  • Figure US20080319221A1-20081225-C00015
  • with a compound of formula VI
  • Figure US20080319221A1-20081225-C00016
  • wherein Hal is chosen from Br, Cl, and l, and
      • R1 is an alkyl radical which has from 1 to 18 carbon atoms and in which at least one —CH2— group of the alkyl radical is optionally replaced by at least one group chosen from —O—, —CO—, —CH═CH—, —C≡C—, and aryl groups, and
      • the alkyl radical is optionally substituted by at least one halogen chosen from F, Cl, Br, and l,
  • to form a compound of formula V
  • Figure US20080319221A1-20081225-C00017
  • b) reacting the compound of formula V with monobenzyl ester of dodecanedioic acid of formula IV to form a compound of formula VIII
  • Figure US20080319221A1-20081225-C00018
  • c) reacting the compound of formula VIII with D-glucamine to form the compound of formula I.
  • Also provided is a process of preparing a compound of formula I
  • Figure US20080319221A1-20081225-C00019
  • comprising converting a compound of formula V
  • Figure US20080319221A1-20081225-C00020
  • to the compound of formula I.
  • Also provided is a process of preparing a compound of formula I
  • Figure US20080319221A1-20081225-C00021
  • comprising converting a compound of formula Va
  • Figure US20080319221A1-20081225-C00022
  • to the compound of formula I.
  • Also provided is a process for preparing a compound of formula Va
  • Figure US20080319221A1-20081225-C00023
  • comprising reacting a compound of formula IV
  • Figure US20080319221A1-20081225-C00024
  • with a compound of formula VIa
  • Figure US20080319221A1-20081225-C00025
  • wherein Hal is chosen from Br, Cl, and l to form a compound of formula Va.
  • Also provided is a process for preparing a compound of formula I
  • Figure US20080319221A1-20081225-C00026
  • comprising reacting a compound of formula Va
  • Figure US20080319221A1-20081225-C00027
  • with D-glucamine to form the compound of formula I.
  • Also provided is a process for preparing a compound of formula VIII
  • Figure US20080319221A1-20081225-C00028
  • comprising
  • a) reacting a compound of formula IV
  • Figure US20080319221A1-20081225-C00029
  • with a compound of formula VIa
  • Figure US20080319221A1-20081225-C00030
  • wherein Hal is chosen from Br, Cl, and l, to form a compound of formula Va
  • Figure US20080319221A1-20081225-C00031
  • and,
  • b) reacting the compound of formula Va with a compound of formula IV to form the compound of formula VIII.
  • Also provided is a process for preparing a compound of formula I
  • Figure US20080319221A1-20081225-C00032
  • comprising reacting a compound of formula VIII
  • Figure US20080319221A1-20081225-C00033
  • with D-glucamine to form the compound of formula I.
  • Also provided is a compound of formula I
  • Figure US20080319221A1-20081225-C00034
  • Also provided is a compound of formula A
  • Figure US20080319221A1-20081225-C00035
  • wherein n is an integer from 6 to 17.
  • Also provided is a compound of formula V
  • Figure US20080319221A1-20081225-C00036
  • Also provided is a compound of formula Va
  • Figure US20080319221A1-20081225-C00037
  • Also provided is a compound of formula VIII
  • Figure US20080319221A1-20081225-C00038
  • Other aspects and embodiments will be apparent to those skilled in the art from the following detailed description.
  • As used herein, the following words and phrases are generally intended to have the meanings as set forth below, except to the extent that the context in which they are used indicates otherwise.
  • As used herein, an alkyl radical is a straight-chain or branched hydrocarbon chain having from one to eighteen carbon atoms, e.g. methyl, ethyl, isopropyl, n-butyl, isobutyl, tert-butyl, hexyl, heptyl, octyl.
  • As used herein, an aryl radical is a phenyl, naphthyl, or biphenyl radical in which at least one CH group is optionally replaced by O, N, or S. The aryl radicals are optionally substituted by at least one suitable group, e.g.: F, Cl, Br, l, CF3, NO2, CN, COO(C1-C6)alkyl, CON[(C1-C6)alkyl]2, cycloalkyl, (C1-C10)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, O—(C1-C6)-alkyl, O—(C2-C6)-alkenyl, O—(C2-C6)-alkynyl, O—CO—(C1-C6)-alkyl, O—CO—(C1-C6)-aryl, O—CO—(C1-C6)-heterocycle, SO2N[(C1-C6)-alkyl]2, S—(C1-C6)-alkyl, N((C1-C6)-alkyl)2.
  • As described herein, “glucamine” refers to a compound according to the formula:
  • Figure US20080319221A1-20081225-C00039
  • a stereoisomer thereof, or a salt thereof. A specific glucamine is D-glucamine represented by the formula:
  • Figure US20080319221A1-20081225-C00040
  • As used herein, the term “reacting” is intended to represent bringing the chemical reactants together under conditions such as to cause the chemical reaction indicated to take place.
  • As use herein, the term “converting” is intended to represent changing one compound into another, for example converting a compound of formula I into a compound of formula II.
  • The compounds described herein may be present in crystalline or amorphous solid forms. Those crystalline forms may include polymorphs and solvates, such as hydrates.
  • Provided is a process for preparing a compound of formula I
  • Figure US20080319221A1-20081225-C00041
  • comprising
  • a) reacting a compound of formula IV
  • Figure US20080319221A1-20081225-C00042
  • with a compound of formula VI
  • Figure US20080319221A1-20081225-C00043
  • wherein
  • Hal is chosen from Br, Cl, and l, and
  • R1 is an alkyl radical which has from 1 to 18 carbon atoms and in which
      • at least one —CH2— group of the alkyl radical is optionally replaced by at least one group chosen from —O—, —CO—, —CH═CH—, —C≡C—, and aryl groups, and
      • the alkyl radical is optionally substituted by at least one halogen chosen from F, Cl, Br, and l,
        to form a compound of formula V
  • Figure US20080319221A1-20081225-C00044
  • and
  • b) reacting the compound of formula V with D-glucamine to form the compound of formula I.
  • In some exemplary embodiments, the compound of formula VI is chosen from alkylcarboxylic halides and alkyl haloformates. In some exemplary embodiments, the compound of formula VI is isobutyl chloroformate.
  • In some exemplary embodiments, Hal is Cl.
  • In some exemplary embodiments, R1 is chosen from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, methyloxy, ethyloxy, propyloxy, isopropyloxy, butyloxy, isobutyloxy, tert-butyloxy, and benzyloxy. In some exemplary embodiments, R1 is isobutyloxy.
  • In some exemplary embodiments, in step a), the compound of formula IV is dissolved in a suitable solvent or solvent mixture in the presence of a suitable base at from −30° C. to 70° C., such as from −10° C. to 40° C., further such as from −5° C. to 0° C. A compound of formula IV may be added over a period of 30-150 minutes, such as 60-120 minutes, to a solution of a compound of formula VI. In some exemplary embodiments, the solution of a compound of formula VI may be cooled to from −10° C. to 30° C., such as from −10 to 0° C.
  • In some exemplary embodiments, in step a), a solution of a compound of formula VI in a suitable solvent or solvent mixture which is cooled to from −10° C. to 30° C., such as from −10° C. to 0° C., is added to a compound of formula IV and a suitable base in a suitable solvent or solvent mixture at from −30° C. to 70° C., such as from −10° C. to 40° C., further such as from −5° C. to 0° C., over a period of 30-150 minutes, such as 60-120 minutes.
  • In some exemplary embodiments, in step a), the reaction mixture is stirred at from −10° C. to 40° C., such as from −10° C. to 0° C., for from 15-150 minutes, such as 30-120 minutes. The reaction mixture may then either be used directly in the subsequent reaction or the product formed is isolated. In some exemplary embodiments, the reaction mixture is used directly. In some exemplary embodiments, the compound of formula V is isolated by evaporation of the solvent(s) under reduced pressure. In some exemplary embodiments, the reaction mixture is washed with water before the evaporation.
  • In some exemplary embodiments, the suitable base used in step a) is chosen from tertiary amines such as triethylamine, ethyldimethylamine, ethyldiisopropylamine, tributylamine, N-ethylmorpholine, tetramethylethylenediamine, guanidine, and alkyl guanidines. In some exemplary embodiments, the suitable base is chosen from triethylamine and ethyldiisopropylamine.
  • In some exemplary embodiments, the suitable solvent used in step a) is chosen from aprotic organic solvents such as toluene, chlorobenzene, dichloromethane, ethyl acetate, butyl acetate, diisobutyl ether, diisopropyl ether, tetrahydrofuran, 2-methyltetrahydrofuran, dimethylformamide, N-methylpyrrolidone, and methyl ethyl ketone. In some exemplary embodiments, the suitable solvent is chosen from ethyl acetate and butyl acetate. In some exemplary embodiments, a mixture of solvents is used.
  • In some exemplary embodiments, in step b), D-glucamine is added a little at a time over a period of from 5-60 minutes, such as 15-30 minutes, to a solution of a compound of formula V and a suitable base in a suitable solvent or solvent mixture at from −10° C. to 40° C., such as from −5° C. to 0° C.
  • In some exemplary embodiments, the suitable base used in step b) is chosen from tertiary amines such as triethylamine, ethyldimethylamine, ethyldiisopropylamine, tributylamine, N-ethylmorpholine, tetramethylethylenediamine, guanidine, and alkyl guanidines. In some exemplary embodiments, the suitable base is chosen from triethylamine and ethyidiisopropylamine.
  • In some exemplary embodiments, the suitable solvent used in step b) is chosen from aprotic organic solvents such as toluene, chlorobenzene, dichloromethane, ethyl acetate, butyl acetate, diisobutyl ether, diisopropyl ether, tetrahydrofuran, 2-methyltetrahydrofuran, dimethylformamide, N-methylpyrrolidone, and methyl ethyl ketone. In some embodiments, the suitable solvent is chosen from ethyl acetate and butyl acetate. In some exemplary embodiments, a mixture of solvents is used.
  • In some exemplary embodiments, the reaction mixture of step b) is stirred for a further period of from 5-120 minutes, such as 30-60 minutes, at from −10° C. to 40° C., such as from −5° C. to 0° C., subsequently for a further 5-20 hours, such as 12 hours, at from 0 to 30° C., such as from 15° C. to 20° C., and subsequently washed with water at 10° C. to 80° C., such as 50° C. to 70° C., and further such as 60° C. The mixture is subsequently cooled to a temperature sufficient to induce crystallization of the compound of formula I, such as 20° C. In some exemplary embodiments, the compound of formula I is purified by recrystallization.
  • Also provided is a process for preparing a compound of formula I
  • Figure US20080319221A1-20081225-C00045
  • comprising
  • a) reacting a compound of formula IV
  • Figure US20080319221A1-20081225-C00046
  • with a compound of formula VI
  • Figure US20080319221A1-20081225-C00047
  • wherein Hal is chosen from Br, Cl, and l, and
  • R1 is an alkyl radical which has from 1 to 18 carbon atoms and in which
      • at least one —CH2— group of the alkyl radical is optionally replaced by at least one group chosen from —O—, —CO—, —CH═CH—, —C≡C—, and aryl groups, and
      • the alkyl radical is optionally substituted by at least one halogen chosen from F, Cl, Br, and l,
        to form a compound of formula V
  • Figure US20080319221A1-20081225-C00048
  • b) reacting the compound of formula V with the compound of formula IV to form a compound of formula VIII
  • Figure US20080319221A1-20081225-C00049
  • c) reacting the compound of formula VIII with D-glucamine to form the compound of formula I.
  • In some exemplary embodiments, the compound of formula VI is chosen from alkylcarboxylic halides and alkyl haloformates. In some exemplary embodiments, the compound of formula VI is isobutyl chloroformate.
  • In some exemplary embodiments, Hal is Cl.
  • In some exemplary embodiments, R1 is chosen from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, methyloxy, ethyloxy, propyloxy, isopropyloxy, butyloxy, isobutyloxy, tert-butyloxy, and benzyloxy. In some exemplary embodiments, R1 is isobutyloxy.
  • In some exemplary embodiments, in step a), the compound of formula IV is dissolved in a suitable solvent or solvent mixture in the presence of at least one base at from −30° C. to 70° C., such as from −10° C. to 40° C., further such as from −5° C. to 0° C., and added over a period of 30-150 minutes, such as 60-120 minutes, to a solution of compound of formula VI which is cooled to from −10° C. to 30° C., such as from −10 to 0° C.
  • In some exemplary embodiments, in step a), a solution of a compound of formula VI in a suitable solvent or solvent mixture is cooled to from −10° C. to 30° C., such as from −10° C. to 0° C., in a reaction vessel and then is added to a compound of formula IV and a suitable base in a suitable solvent or solvent mixture at from −30° C. to 70° C., such as from −10° C. to 40° C., further such as from −5° C. to 0° C., over a period of 30-150 minutes, such as 60-120 minutes.
  • In some exemplary embodiments, the reaction mixture in step a) is stirred at from −10° C. to 40° C., such as from −10° C. to 0° C., for from 15-150 minutes, such as 30-120 minutes. The reaction mixture can then either be used directly in the subsequent reaction or the product formed is isolated. In some exemplary embodiments, the reaction mixture is used directly. In some exemplary embodiments, the compound of formula V is isolated by evaporation under reduced pressure. In some exemplary embodiments, the reaction mixture is washed with water before the evaporation.
  • In some exemplary embodiments, the suitable base used in step a) is chosen from tertiary amines such as triethylamine, ethyldimethylamine, ethyldiisopropylamine, tributylamine, N-ethylmorpholine, tetramethylethylenediamine, guanidine, and alkyl guanidines. In some exemplary embodiments, the suitable base is chosen from triethylamine and ethyidiisopropylamine.
  • In some exemplary embodiments, the suitable solvent used in step a) is chosen from customary organic solvents such as toluene, chlorobenzene, dichloromethane, ethyl acetate, butyl acetate, diisobutyl ether, diisopropyl ether, tetrahydrofuran, 2-methyltetrahydrofuran, dimethylformamide, N-methylpyrrolidone, or methyl ethyl ketone. In some exemplary embodiments, the suitable solvent is ethyl acetate or butyl acetate. In some exemplary embodiments, a mixture of solvents is used.
  • In some exemplary embodiments, in step b), the compound of formula IV is added a little at a time to a solution of product V and optionally a suitable base in a suitable solvent or solvent mixture at from −10° C. to 40° C., such as from 0° C. to 25° C., over a period of 5-60 minutes, such as 15-30 minutes.
  • In some exemplary embodiments, the suitable base used in step b) is chosen from tertiary amines such as triethylamine, ethyldimethylamine, ethyldiisopropylamine, tributylamine, N-ethylmorpholine, tetramethylethylenediamine, guanidine, and alkyl guanidines. In some exemplary embodiments, the suitable base is chosen from triethylamine and ethyidiisopropylamine.
  • In some exemplary embodiments, the suitable solvent used in step b) is chosen from aprotic organic solvents such as toluene, chlorobenzene, dichloromethane, ethyl acetate, butyl acetate, diisobutyl ether, diisopropyl ether, tetrahydrofuran, 2-methyltetrahydrofuran, dimethylformamide, N-methylpyrrolidone, and methyl ethyl ketone. In some exemplary embodiments, the suitable solvent is chosen from ethyl acetate and butyl acetate. In some exemplary embodiments, a mixture of solvents is used.
  • In some exemplary embodiments, the reaction mixture of step b) is stirred at from −10° C. to 40° C., such as from 0° C. to 25° C., for another 5-240 minutes, such as 60-150 minutes. In some exemplary embodiments, the precipitate formed is filtered and dried, giving a compound of formula VIII.
  • In some exemplary embodiments, in step c), D-glucamine is added a little at a time to a solution of product VIII and optionally a suitable base in a suitable solvent or solvent mixture at from −10° C. to 40° C., such as from −5° C. to 5° C., over a period of from 5-60 minutes, such as 15-30 minutes.
  • In some exemplary embodiments, the suitable base used in step c) is chosen from tertiary amines such as triethylamine, ethyldimethylamine, ethyldiisopropylamine, tributylamine, N-ethylmorpholine, tetramethylethylenediamine, guanidine, and alkyl guanidines. In some exemplary embodiments, the suitable base is chosen from triethylamine and ethyidiisopropylamine.
  • In some exemplary embodiments, the suitable solvent used in step c) is chosen from aprotic organic solvents such as toluene, chlorobenzene, dichloromethane, ethyl acetate, butyl acetate, diisobutyl ether, diisopropyl ether, tetrahydrofuran, 2-methyltetrahydrofuran, dimethylformamide, N-methylpyrrolidone, and methyl ethyl ketone. In some exemplary embodiments, the suitable solvent is chosen from ethyl acetate and butyl acetate. In some exemplary embodiments, a mixture of solvents is used.
  • In some exemplary embodiments, the reaction mixture in step c) is stirred at from −10° C. to 40° C., such as from 10° C. to 25° C., for another 1-20 hours, such as 10-18 hours, and subsequently washed with water at 10° C. to 80° C., such as 50° C. to 70° C. The mixture is subsequently cooled to a temperature sufficient to induce crystallization of the compound of formula I, such as 20° C. In some exemplary embodiments, the compound of formula I is purified by recrystallization.
  • In some exemplary embodiments, the compound of formula I, which may be obtained as described herein, is converted into a compound of formula II
  • Figure US20080319221A1-20081225-C00050
  • In some exemplary embodiments, converting the compound of formula I into a compound of formula II comprises reacting the compound of formula I under alkaline conditions, using, for example, aqueous sodium hydroxide or aqueous potassium hydroxide.
  • In some embodiments, converting the compound of formula I into a compound of formula II comprises reacting the compound of formula I under enzymatic conditions to form formula II. Non-limiting examples of suitable enzymes include lipases, for example Candida.
  • In some exemplary embodiments, converting the compound of formula I into a compound of formula II comprises hydrogenating the compound of formula I under suitable conditions.
  • In some exemplary embodiments, hydrogenating the compound of formula I comprises reacting the compound of formula I with a hydrogen source in the presence of a hydrogenation catalyst. In some exemplary embodiments, a hydrogenation catalyst, such as palladium on carbon (Pd/C), Raney-Nickel, platinum, platinum oxide, or zinc oxide is used. In some exemplary embodiments, the hydrogen source is chosen from hydrogen gas and ammonium formate.
  • Also provided is a process for preparing a compound of formula III
  • Figure US20080319221A1-20081225-C00051
  • comprising
  • a) reacting a compound of formula IV
  • Figure US20080319221A1-20081225-C00052
  • with a compound of formula VI
  • Figure US20080319221A1-20081225-C00053
  • wherein Hal is chosen from Br, Cl, and l, and
  • R1 is an alkyl radical which has from 1 to 18 carbon atoms and in which
      • at least one —CH2— group of the alkyl radical is optionally replaced by at least one group chosen from —O—, —CO—, —CH═CH—, —C≡C—, and aryl groups, and
      • the alkyl radical is optionally substituted by at least one halogen chosen from F, Cl, Br, and l,
        to form a compound of formula V
  • Figure US20080319221A1-20081225-C00054
  • b) reacting the compound of formula V with D-glucamine to form the compound of formula I
  • Figure US20080319221A1-20081225-C00055
  • c) converting the compound of formula I into a compound of formula II
  • Figure US20080319221A1-20081225-C00056
  • d) reacting the compound of formula II with a compound of formula VII
  • Figure US20080319221A1-20081225-C00057
  • to form a compound of formula III.
  • In some exemplary embodiments, the reaction conditions for the preparation of a compound of formula V, a compound of formula I, and a compound of formula II are as described herein.
  • In some exemplary embodiments, reacting the compound of formula II with a compound of formula VII comprises reacting the compound of formula II with suitable peptide coupling reagents in a suitable solvent or solvent mixture, and then further reacting with a compound of formula VII. Suitable peptide coupling reagents and solvents or solvent mixtures are described, inter alia, in, for example, A. Speicher et al. In Journal für Praktische Chemie/Chemiker-Zeitung (1998), 340, 581-583; Y. S. Klausner and M. Bodansky, Synthesis, (1972), 453 et seq.; K. Ishihara et al., J. Org. Chem., 61, 4196 (1996); M. Kunishima et al., Tetrahedron 55,13159-13170 (1999), or R. C. Larock: Comprehensive Organic Transformations; VCH, New York, 1989, page 981 et. seq.
  • The reaction of the compound of formula II with the amine of formula VII is described, for example, in WO 02/50027 or U.S. Pat. No. 7,205,290.
  • Also provided herein is a process for preparing a compound of formula III
  • Figure US20080319221A1-20081225-C00058
  • comprising
  • a) reacting a compound of formula IV
  • Figure US20080319221A1-20081225-C00059
  • with a compound of formula VI
  • Figure US20080319221A1-20081225-C00060
  • wherein Hal is chosen from Br, Cl, and l, and
  • R1 is an alkyl radical which has from 1 to 18 carbon atoms and in which
      • at least one —CH2— group of the alkyl radical is optionally replaced by at least one group chosen from —O—, —CO—, —CH═CH—, —C≡C—, and aryl groups, and
      • the alkyl radical is optionally substituted by at least one halogen chosen from F, Cl, Br, and l,
        to form a compound of formula V
  • Figure US20080319221A1-20081225-C00061
  • b) reacting the compound of formula V with monobenzyl ester of dodecanedioic acid of formula IV to form a compound of formula VIII
  • Figure US20080319221A1-20081225-C00062
  • c) reacting the compound of formula VIII with D-glucamine to form the compound of formula I
  • Figure US20080319221A1-20081225-C00063
  • d) converting the compound of formula I into a compound of formula II
  • Figure US20080319221A1-20081225-C00064
  • e) reacting the compound of formula II with a compound of formula VII
  • Figure US20080319221A1-20081225-C00065
  • to form a compound of formula III.
  • In some exemplary embodiments, the reaction conditions for the preparation of a compound of formula V, a compound of formula VIII, a compound of formula I, a compound of formula II, and a compound of formula III are as described herein.
  • Also provided is a process of preparing a compound of formula I
  • Figure US20080319221A1-20081225-C00066
  • comprising converting a compound of formula V
  • Figure US20080319221A1-20081225-C00067
  • to the compound of formula I.
  • In some exemplary embodiments, the reaction conditions for the preparation of a compound of formula I from a compound of formula V are as described herein.
  • Also provided is a process of preparing a compound of formula I
  • Figure US20080319221A1-20081225-C00068
  • comprising converting a compound of formula Va
  • Figure US20080319221A1-20081225-C00069
  • to the compound of formula I.
  • In some exemplary embodiments, the reaction conditions for the preparation of a compound of formula I from a compound of formula Va are as described herein.
  • Also provided is a process for preparing a compound of formula Va
  • Figure US20080319221A1-20081225-C00070
  • comprising reacting a compound of formula IV
  • Figure US20080319221A1-20081225-C00071
  • with a compound of formula Via
  • Figure US20080319221A1-20081225-C00072
  • wherein Hal is chosen from Br, Cl, and l to form a compound of formula Va.
  • In some exemplary embodiments, the processes for the preparation of a compound of formula Va from a compound of formula IV are as described herein.
  • Also provided is a process for preparing a compound of formula I
  • Figure US20080319221A1-20081225-C00073
  • comprising reacting a compound of formula Va
  • Figure US20080319221A1-20081225-C00074
  • with D-glucamine to form the compound of formula I.
  • In some exemplary embodiments, the reaction conditions for the preparation of a compound of formula I from a compound of formula Va are as described herein.
  • Also provided is a process for preparing a compound of formula VIII
  • Figure US20080319221A1-20081225-C00075
  • comprising
  • a) reacting a compound of formula IV
  • Figure US20080319221A1-20081225-C00076
  • with a compound of formula Via
  • Figure US20080319221A1-20081225-C00077
  • wherein Hal is chosen from Br, Cl, and l, to form a compound of formula Va
  • Figure US20080319221A1-20081225-C00078
  • and,
  • b) reacting the compound of formula Va with the compound of formula IV to form the compound of formula VII.
  • In some exemplary embodiments, the reaction conditions for the preparation of a compound of formula Va from a compound of formula IV and for the preparation of a compound of formula VIII from a compound of formula Va are as described herein.
  • Also provided is a process for preparing a compound of formula I
  • Figure US20080319221A1-20081225-C00079
  • comprising reacting a compound of formula VIII
  • Figure US20080319221A1-20081225-C00080
  • with D-glucamine to form the compound of formula I.
  • In some exemplary embodiments, the reaction conditions for the preparation of a compound of formula I from a compound of formula VIII are as described herein.
  • Also provided is a compound of formula Va.
  • Figure US20080319221A1-20081225-C00081
  • Also provided is a compound of formula VIII.
  • Figure US20080319221A1-20081225-C00082
  • EXAMPLES
  • The following examples serve to more fully describe the manner of using the invention. These examples are presented for illustrative purposes and should not serve to limit the true scope of the invention.
  • 1. Preparation of Benzyl 12-isobutoxycarbonyloxy-12-oxododecanoate (Va)
  • 1.5 g (4.7 mmol) of the monobenzyl ester of dodecanedioic acid together with 15 ml of ethyl acetate are placed in a reaction vessel and admixed with 0.8 ml (5.6 mmol) of triethylamine. The mixture is cooled to −5° C. and a solution of 0.7 ml (5.0 mmol) of isobutyl chloroformate is added. After 60 minutes, the precipitate is filtered off with suction under protective gas, washed twice with ethyl acetate, and the filtrate is evaporated to dryness to obtain benzyl 12-isobutoxycarbonyloxy-12-oxododecanoate (Va).
  • 2. Preparation of Benzyl 11-(2S,3R,4R,5R-2,3,4,5,6-pentahydroxyhexylcarbamoyl)undecanoate I from Benzyl 12-isobutoxycarbonyloxy-12-oxododecanoate (Va)
  • Benzyl 12-isobutoxycarbonyloxy-12-oxododecanoate is dissolved in 15 ml of ethyl acetate and admixed at 0° C. with 0.9 g (5.2 mmol) of 2R,3R,4R,5S-6-aminohexane-1,2,3,4,5-pentanol (D-glucamine). The mixture is stirred at 0° C. for one hour, warmed to 20° C. and allowed to stand overnight. The white suspension formed is shaken three times at 65° C. with 20 ml of water at the same temperature. The organic phase is subsequently evaporated to dryness to obtain benzyl 11-(2S,3R,4R,5R-2,3,4,5,6-pentahydroxyhexylcarbamoyl)undecanoate (I).
  • 3. Preparation of the Anhydride of Dodecanedicarboxylic Monobenzyl Ester (VIII) from benzyl 12-isobutoxycarbonyloxy-12-oxododecanoate (Va)
  • Benzyl 12-isobutoxycarbonyloxy-12-oxododecanoate is admixed with 20 ml of ethyl acetate and admixed at 20° C. with 1.9 g (4.2 mmol) of the monobenzyl ester of dodecanedioic acid. The mixture is stirred for 2.5 hours, and the precipitate formed is filtered off and dried to obtain anhydride of dodecanedicarboxylic monobenzyl ester (VIII).
  • 4. Preparation of Benzyl 11-(2S,3R,4R,5R-2,3,4,5,6-pentahydroxyhexylcarbamoyl)undecanoate (I) from the Anhydride of Dodecanedioic Acid Monobenzyl Ester (VIII)
  • 0.50 g (0.80 mmol) of the anhydride of dodecanedioic acid monobenzyl ester (VIII) together with 10 ml of ethyl acetate are placed in a reaction vessel and admixed with 0.14 ml (0.96 mmol) of triethylamine and the mixture is cooled to 0° C. A suspension of 0.16 g (0.88 mmol) of 2R,3R,4R,5S-6-aminohexane-1,2,3,4,5-pentanol (D-glucamine) in 6 ml of ethyl acetate is added and the mixture is stirred at room temperature for 18 hours. The mixture is heated to 70° C. and shaken three times with 20 ml of water at the same temperature. The organic phase is allowed to cool to room temperature, and the precipitate formed is filtered off and dried to obtain benzyl 11-(2S,3R,4R,5R-2,3,4,5,6-pentahydroxyhexylcarbamoyl)undecanoate (I).
  • 5. Preparation of Benzyl 11-(2S,3R,4R,5R-2,3,4,5,6-pentahydroxyhexylcarbamoyl)undecanoate (I) from the Monobenzyl Ester of Dodecanedioic Acid (IVa) without Isolation of the Intermediates
  • 17 kg of isobutyl chloroformate together with 150 L of ethyl acetate are placed in a reaction vessel and cooled to −5° C. A solution of 37.3 kg of the monobenzyl ester of dodecanedioic acid and 14.2 kg of triethylamine in 100 L of ethyl acetate which has been cooled to −5° C. is added to the above solution over a period of 2 hours. After the addition is complete to form a compound of formula Va, the mixture is stirred at −5° C. for another 2 hours. 23.2 kg of D-glucamine are then added a little at a time at −5° C. over a period 30 minutes and, after the addition is complete, the mixture is stirred at −5° C. for another 1 hour and subsequently at 20° C. for 12 hours. The reaction mixture is poured into 200 L of ethyl acetate and 300 L of water, the mixture is heated to 65° C., and the phases are separated. The organic phase is washed at 60° C. with a further 80 L of water and the organic phase is subsequently cooled to 20° C. over a period of 60 minutes. After stirring for another 1 hour, the precipitated solid is filtered off and dried to obtain benzyl 11-(2S,3R,4R,5R-2,3,4,5,6-pentahydroxyhexylcarbamoyl)undecanoate (I).
  • Subsequent experiments produced a compound of formula (II) from a compound of formula (I) under various conditions, including basic reaction conditions, enzymatic reaction conditions, and hydrogenation reaction conditions, utilizing Pd/C and hydrogen, and experiments were also performed to further produce from a compound of formula (II) a compound of formula (III), which has use for treating hyperlipidemia and arteriosclerosis and hypercholesterolemia as described in U.S. Pat. No. 7,205,290.
  • While the present invention has been described with reference to the specific embodiments thereof, it should be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the true spirit and scope of the invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process step, or steps, and all such modifications are intended to be within the scope of the claims appended hereto.

Claims (2)

1. A compound of formula A:
Figure US20080319221A1-20081225-C00083
wherein n is an integer from 6 to 17.
2. A compound of formula I:
Figure US20080319221A1-20081225-C00084
US11/767,298 2007-06-22 2007-06-22 Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids Abandoned US20080319221A1 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
US11/767,298 US20080319221A1 (en) 2007-06-22 2007-06-22 Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
BRPI0813120A BRPI0813120A2 (en) 2007-06-22 2008-06-07 process for preparing benzyl pentahydroxyhexylcarbamoylundecanoate
CA2691065A CA2691065A1 (en) 2007-06-22 2008-06-07 Process for preparing benzyl pentahydroxyhexylcarbamoylundecanoate
AU2008267515A AU2008267515A1 (en) 2007-06-22 2008-06-07 Process for preparing benzyl pentahydroxyhexylcarbamoylundecanoate
KR1020097026689A KR20100023886A (en) 2007-06-22 2008-06-07 Process for preparing benzyl pentahydroxyhexylcarbamoylundecanoate
MX2009012727A MX2009012727A (en) 2007-06-22 2008-06-07 Process for preparing benzyl pentahydroxyhexylcarbamoylundecanoat e.
CN200880021496A CN101687769A (en) 2007-06-22 2008-06-07 Process for preparing benzyl pentahydroxyhexylcarbamoylundecanoate
PCT/EP2008/004552 WO2009000397A1 (en) 2007-06-22 2008-06-07 Process for preparing benzyl pentahydroxyhexylcarbamoylundecanoate
ARP080102606A AR068977A1 (en) 2007-06-22 2008-06-19 PROCEDURE FOR THE PREPARATION OF PENTAHYDROXIHEXILCARBAMOILUNDECANOATE OF BENCILO AND INTERMEDIATE COMPOUND USED IN THE MANUFACTURE OF THE SAME
TW097122784A TW200914406A (en) 2007-06-22 2008-06-19 Process for the preparation of benzyl pentahydroxyhexylcarbamoylundecanoate
UY31165A UY31165A1 (en) 2007-06-22 2008-06-20 PROCEDURE FOR THE PREPARATION OF PENTAHYDROXIHEXILCARBAMOILUNDECANOATE OF BENCILO
CL200801857A CL2008001857A1 (en) 2007-06-22 2008-06-20 PROCEDURES FOR THE PREPARATION OF 11- (2,3,4,5,6-PENTAHYDROXI-HEXILCARBAMOIL) -BUNDYLOCATE OF BENCILO; INTERMEDIARY COMPOUND; AND ITS PREPARATION PROCEDURE.
US12/271,236 US7678935B2 (en) 2007-06-22 2008-11-14 Esters of pentahydroxyhexylcarbamoyl alkanoic acids
IL202824A IL202824A0 (en) 2007-06-22 2009-12-17 Process for preparing benzyl pentahydroxyhexylcarbamoylundecanoate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/767,298 US20080319221A1 (en) 2007-06-22 2007-06-22 Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/271,236 Continuation US7678935B2 (en) 2007-06-22 2008-11-14 Esters of pentahydroxyhexylcarbamoyl alkanoic acids

Publications (1)

Publication Number Publication Date
US20080319221A1 true US20080319221A1 (en) 2008-12-25

Family

ID=40137195

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/767,298 Abandoned US20080319221A1 (en) 2007-06-22 2007-06-22 Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
US12/271,236 Expired - Fee Related US7678935B2 (en) 2007-06-22 2008-11-14 Esters of pentahydroxyhexylcarbamoyl alkanoic acids

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/271,236 Expired - Fee Related US7678935B2 (en) 2007-06-22 2008-11-14 Esters of pentahydroxyhexylcarbamoyl alkanoic acids

Country Status (1)

Country Link
US (2) US20080319221A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080318870A1 (en) * 2007-06-19 2008-12-25 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
US20090270642A1 (en) * 2008-04-25 2009-10-29 Kythera Biopharmaceuticals, Inc. Preparation of bile acids and intermediates thereof
US20100160276A1 (en) * 2007-06-19 2010-06-24 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
US8003636B2 (en) 2007-11-13 2011-08-23 Sanofi-Aventis Deutschland Gmbh Certain crystalline diphenylazetidinone hydrates, pharmaceutical compositions thereof and methods for their use
US9127036B2 (en) 2010-08-12 2015-09-08 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
US9563700B2 (en) * 2015-05-19 2017-02-07 Spotify Ab Cadence-based playlists management system

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067689B1 (en) * 2005-07-08 2006-06-27 Microbia, Inc. Process for production of pentahydroxyhexylcarbamoyl alkanoic acids

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0124317B1 (en) * 1983-04-27 1990-04-11 Ici Americas Inc. Proline derivatives
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
CN1103780C (en) 1995-10-31 2003-03-26 先灵公司 Sugar-substituted 2-azetidinones useful as hypocholesterolemic gents
US6225310B1 (en) 1996-01-17 2001-05-01 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
CN1158290C (en) 1996-01-17 2004-07-21 诺沃挪第克公司 Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
US5739321A (en) 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
CN1271086C (en) 1996-08-30 2006-08-23 诺沃挪第克公司 GLP-1 derivs.
US5756470A (en) 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
UA64713C2 (en) 1996-12-31 2004-03-15 Reddys Lab Ltd Dr Azolidinedione derivatives, a method for producing thereof (variants), pharmaceutical compositions based thereon, a method for prevention or treatment, a method for lowering glucose level and an intermediate compound
KR20010021936A (en) 1997-07-16 2001-03-15 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 Fused 1,2,4-thiadiazine derivatives, their preparation and use
AR023463A1 (en) 1999-04-16 2002-09-04 Schering Corp USE OF AZETIDINONE COMPOUNDS
IT1314184B1 (en) * 1999-08-12 2002-12-06 Nicox Sa PHARMACEUTICAL COMPOSITIONS FOR THE THERAPY OF STRESS-OXIDATIVE CONDITIONS
DE60128475T2 (en) 2000-07-25 2008-02-07 Merck & Co., Inc. N-SUBSTITUTED INDOLE USED IN THE TREATMENT OF DIABETES
NZ526593A (en) 2000-12-21 2005-02-25 Aventis Pharma Gmbh Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
DE10314610A1 (en) 2003-04-01 2004-11-04 Aventis Pharma Deutschland Gmbh New diphenylazetidinone with improved physiological properties, process for its preparation, medicaments containing these compounds and its use
DE102007063671A1 (en) 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh New crystalline diphenylazetidinone hydrates, medicaments containing these compounds and their use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067689B1 (en) * 2005-07-08 2006-06-27 Microbia, Inc. Process for production of pentahydroxyhexylcarbamoyl alkanoic acids

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9987291B2 (en) 2007-06-19 2018-06-05 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
US20080318870A1 (en) * 2007-06-19 2008-12-25 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
US9050349B2 (en) 2007-06-19 2015-06-09 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
US11202786B2 (en) 2007-06-19 2021-12-21 Allergan Sales, Llc Synthetic bile acid compositions and methods
US11026955B2 (en) 2007-06-19 2021-06-08 Allergan Sales, Llc Synthetic bile acid compositions and methods
US10434108B2 (en) 2007-06-19 2019-10-08 Allergan Sales, Llc Synthetic bile acid compositions and methods
US10434107B2 (en) 2007-06-19 2019-10-08 Allergan Sales, Llc Synthetic bile acid compositions and methods
US20100160276A1 (en) * 2007-06-19 2010-06-24 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
US8883770B2 (en) 2007-06-19 2014-11-11 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
US9949986B2 (en) 2007-06-19 2018-04-24 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
US8242294B2 (en) 2007-06-19 2012-08-14 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
US9636349B2 (en) 2007-06-19 2017-05-02 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
US9522155B2 (en) 2007-06-19 2016-12-20 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
US8461140B2 (en) 2007-06-19 2013-06-11 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
US8546367B2 (en) 2007-06-19 2013-10-01 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
US8003636B2 (en) 2007-11-13 2011-08-23 Sanofi-Aventis Deutschland Gmbh Certain crystalline diphenylazetidinone hydrates, pharmaceutical compositions thereof and methods for their use
US20110224448A1 (en) * 2008-04-25 2011-09-15 Kythera Biopharmaceuticals, Inc. Preparation of bile acids and intermediates thereof
US10053486B2 (en) 2008-04-25 2018-08-21 Kythera Biopharmaceuticals, Inc. Preparation of bile acids and intermediates thereof
US7902387B2 (en) * 2008-04-25 2011-03-08 Kythera Biopharmaceuticals, Inc. Preparation of bile acids and intermediates thereof
US8367852B2 (en) 2008-04-25 2013-02-05 Kythera Biopharmaceuticals, Inc. Preparation of bile acids and intermediates thereof
US20100145083A1 (en) * 2008-04-25 2010-06-10 Kythera Biopharmaceuticals, Inc. Preparation of bile acids and intermediates thereof
US8362285B2 (en) 2008-04-25 2013-01-29 Kythera Biopharmaceuticals, Inc. Preparation of bile acids and intermediates thereof
US20100179337A2 (en) * 2008-04-25 2010-07-15 Kythera Biopharmaceuticals, Inc. Preparation of bile acids and intermediates thereof
US20090270642A1 (en) * 2008-04-25 2009-10-29 Kythera Biopharmaceuticals, Inc. Preparation of bile acids and intermediates thereof
US7994351B2 (en) 2008-04-25 2011-08-09 Kythera Biopharmaceuticals, Inc. Preparation of bile acids and intermediates thereof
US11008363B2 (en) 2008-04-25 2021-05-18 Allergan Sales, Llc Preparation of bile acids and intermediates thereof
US10633412B2 (en) 2008-04-25 2020-04-28 Allergan Sales, Llc Preparation of bile acids and intermediates thereof
US20110152552A1 (en) * 2008-04-25 2011-06-23 Kythera Biopharmaceuticals, Inc. Preparation of bile acids and intermediates thereof
US9150607B2 (en) 2008-04-25 2015-10-06 Kythera Biopharmaceuticals, Inc. Preparation of bile acids and intermediates thereof
US10144757B2 (en) 2010-08-12 2018-12-04 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
US9683008B2 (en) 2010-08-12 2017-06-20 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
US9127036B2 (en) 2010-08-12 2015-09-08 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
US11500924B2 (en) 2015-05-19 2022-11-15 Spotify Ab Cadence-based playlists management system
US9563700B2 (en) * 2015-05-19 2017-02-07 Spotify Ab Cadence-based playlists management system
US11868397B2 (en) 2015-05-19 2024-01-09 Spotify Ab Cadence-based playlists management system

Also Published As

Publication number Publication date
US20090082589A1 (en) 2009-03-26
US7678935B2 (en) 2010-03-16

Similar Documents

Publication Publication Date Title
US7678935B2 (en) Esters of pentahydroxyhexylcarbamoyl alkanoic acids
US7279595B2 (en) Process for the preparation of high purity perindopril
US20090312576A1 (en) Process and intermediates for the preparation of 3-(amino)-3-cyclobutylmethyl-2-hydroxy-propionamide or salts thereof
JP6482465B2 (en) Preparation method of pregabalin
US20090131707A1 (en) Chemical process for the preparation of intermediates to obtain n-formyl hydroxylamine compounds
RU2029761C1 (en) Process for preparing 1-(aminomethyl) cyclohexaneacetic acid
US20110124899A1 (en) Method for preparing combretastatin
US4910320A (en) Process for preparing 3-pyrrolidinol
US10414720B2 (en) Process for the preparation of lacosamide
US8957252B2 (en) Process for preparation of lacosamide and some N-benzyl-propanamide intermediate derivatives
US20080319218A1 (en) Processes for Making and Using Benzyl Pentahydroxyhexylcarbamoylundecanoate
US7601869B2 (en) Process for the preparation of Florfenicol
US6977311B2 (en) Process for synthesizing L-γ-methylene glutamic acid and analogs
US5663365A (en) Process for the preparation of pyrazolones
Kurz et al. O-Protected 3-hydroxy-oxazolidin-2, 4-diones: novel precursors in the synthesis of α-hydroxyhydroxamic acids
KR0150288B1 (en) Novel carbamate compounds containing thiocarbamoyl group and process for preparing the same
US6900326B2 (en) Method of producing N-alkoxycarbonylpiperidine derivative, new compound as raw material therefor, and method of producing the compound
US7960558B2 (en) Pharmaceutical intermediate for synthesizing ACE inhibitors and the use thereof
JP4323032B2 (en) Process for producing 3-nitro-2- (Nt-butoxycarbonyl) aminobenzoates and production intermediates thereof
JP4667589B2 (en) Method for producing 2,4-dihydroxypyridine
US7358394B2 (en) Process for preparing N,N′-dialkoxy-N, N′-dialkyl oxamide
US20070149606A1 (en) Process for producing phenylacetic acid derivative
US20100063280A1 (en) Process for preparing ccr-5 receptor antagonists utilizing 4-substituted 1-cyclopropane-sulfonyl-piperidinyl compounds
JP4384315B2 (en) Method for producing 3-nitro-2- (Nt-butoxycarbonyl) aminobenzoic acid esters and production intermediates thereof
US20220127236A1 (en) Process for the preparation of substituted pyrazole derivatives

Legal Events

Date Code Title Description
AS Assignment

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:JUNKER, BERND;MANERO, JAVIER;REEL/FRAME:019996/0065

Effective date: 20070816

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION